» Articles » PMID: 33143184

Chronic Active Epstein-Barr Virus Infection: Is It Immunodeficiency, Malignancy, or Both?

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2020 Nov 4
PMID 33143184
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic active Epstein-Barr virus (EBV) infection (CAEBV) is a rare syndrome characterized by prolonged infectious mononucleosis-like symptoms and elevated peripheral blood EBV DNA load in apparently immunocompetent persons. CAEBV has been primarily reported in East Asia and Latin America, suggesting a genetic predisposition in its pathogenesis. In most cases of CAEBV, EBV induces proliferation of its unusual host cells, T or natural killer (NK) cells. The clinical course of CAEBV is heterogeneous; some patients show an indolent course, remaining in a stable condition for years, whereas others show an aggressive course with a fatal outcome due to hemophagocytic lymphohistiocytosis, multiple organ failure, or progression to leukemia/lymphoma. The pathogenesis of CAEBV is unclear and clinicopathological investigations suggest that it has aspects of both malignant neoplasm and immunodeficiency. Recent genetic analyses of both viral and host genomes in CAEBV patients have led to discoveries that are improving our understanding of the nature of this syndrome. This article summarizes the latest findings on CAEBV and discusses critical unsolved questions regarding its pathogenesis and disease concept.

Citing Articles

Evaluation of Clinical and Hematological Findings of Patients with Acute and Reactivated EBV Infection.

Bahadir A, Tekin T, Gayretli Aydin Z, Reis G, Erduran E Indian J Hematol Blood Transfus. 2025; 41(1):89-95.

PMID: 39917498 PMC: 11794905. DOI: 10.1007/s12288-024-01792-0.


Role of rapidly evolving immunotherapy in chronic active Epstein-Barr virus disease.

Yan S, Ming X, Zhu X, Xiao Y Front Immunol. 2024; 15:1451977.

PMID: 39691713 PMC: 11649625. DOI: 10.3389/fimmu.2024.1451977.


What Makes It Tick: Exploring the Mechanisms of Post-treatment Lyme Disease Syndrome.

Wester K, Nwokeabia B, Hassan R, Dunphy T, Osondu M, Wonders C Cureus. 2024; 16(7):e64987.

PMID: 39161484 PMC: 11332314. DOI: 10.7759/cureus.64987.


DRB1 locus alleles of HLA class II are associated with modulation of the immune response in different serological profiles of HIV-1/Epstein-Barr virus coinfection in the Brazilian Amazon region.

Pereira L, Franca E, Costa I, Lima I, Jorge E, de Souza Mendonca Mattos P Front Med (Lausanne). 2024; 11:1408290.

PMID: 38933108 PMC: 11199549. DOI: 10.3389/fmed.2024.1408290.


A differential diagnosis method for systemic CAEBV and the prospect of EBV-related immune cell markers via flow cytometry.

Jin J, Mao X, Zhang D Ann Med. 2024; 56(1):2329136.

PMID: 38502913 PMC: 10953786. DOI: 10.1080/07853890.2024.2329136.


References
1.
Smith N, Coleman C, Gewurz B, Rochford R . CD21 (Complement Receptor 2) Is the Receptor for Epstein-Barr Virus Entry into T Cells. J Virol. 2020; 94(11). PMC: 7269432. DOI: 10.1128/JVI.00428-20. View

2.
Watry D, Hedrick J, Siervo S, Rhodes G, Lamberti J, Lambris J . Infection of human thymocytes by Epstein-Barr virus. J Exp Med. 1991; 173(4):971-80. PMC: 2190801. DOI: 10.1084/jem.173.4.971. View

3.
Arai A, Imadome K, Watanabe Y, Yoshimori M, Koyama T, Kawaguchi T . Clinical features of adult-onset chronic active Epstein-Barr virus infection: a retrospective analysis. Int J Hematol. 2011; 93(5):602-609. DOI: 10.1007/s12185-011-0831-x. View

4.
Virelizier J, Lenoir G, Griscelli C . Persistent Epstein-Barr virus infection in a child with hypergammaglobulinaemia and immunoblastic proliferation associated with a selective defect in immune interferon secretion. Lancet. 1978; 2(8083):231-4. DOI: 10.1016/s0140-6736(78)91744-0. View

5.
Arvey A, Ojesina A, Pedamallu C, Ballon G, Jung J, Duke F . The tumor virus landscape of AIDS-related lymphomas. Blood. 2015; 125(20):e14-22. PMC: 4432014. DOI: 10.1182/blood-2014-11-599951. View